|| ISSN(online): 2589-8698 || ISSN(print): 2589-868X ||
International Journal of Medical and Biomedical Studies
Available Online at www.ijmbs.info
NLM (National Library of Medicine ID: 101738825)
Index Copernicus Value 2022: 79.52
Review Article Volume 7, Issue 1; January: 2023; Page No. 79-82

Detection of Drug Resistance in Mycobacterium tuberculosis

Dr. Nazia Tahseen Aqueel

Assistant Professor, Microbiology, Naraina Medical College & Hospital, Ghatampur, Kanpur, Uttar Pradesh - 209206, India

Received: 11-09-2023 / Revised: 15-10-2023 / Accepted: 23-11-2023
Corresponding author: Dr. Nazia Tahseen Aqueel
Conflict of interest: No conflict of interest.

Abstract

Drug-resistant tuberculosis (TB), particularly multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is a growing global health concern. Early and accurate detection of drug-resistant Mycobacterium tuberculosis (Mtb) strains is crucial for effective treatment and prevention of transmission. Conventional phenotypic methods, such as the agar proportion method (APM), and molecular techniques, including GeneXpert MTB/RIF and line probe assays (LPA), are widely used to detect resistance to first-line and second-line drugs. Molecular methods offer faster and more reliable results compared to traditional culture-based methods. This study aims to compare the sensitivity, specificity, and clinical relevance of various diagnostic methods for detecting drug resistance in Mtb. The findings suggest that while molecular methods provide quicker and more accurate results, traditional culture methods remain essential for confirming resistance to second-line drugs. The integration of both approaches into TB control programs is recommended for better management of drug-resistant TB.

Keywords: Mycobacterium tuberculosis, drug resistance, MDR-TB, XDR-TB, detection, GeneXpert MTB/RIF, line probe assays.

Introduction

Tuberculosis (TB) remains one of the leading infectious diseases worldwide, with Mycobacterium tuberculosis (Mtb) being the causative agent. The World Health Organization (WHO) reported over 9 million new TB cases annually, with approximately 1.5 million deaths from TB (1). The development of drug resistance in Mtb has become a significant challenge in TB control. Drug-resistant TB, particularly multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is increasingly common and complicates treatment regimens, leading to longer treatment courses, higher treatment costs, and higher mortality rates (2).

MDR-TB is defined as resistance to at least isoniazid and rifampicin, the two most powerful first-line drugs used in TB treatment (3). XDR-TB, a more severe form of resistance, involves resistance to at least isoniazid, rifampicin, fluoroquinolones, and one of the injectable second-line drugs (4). The development of drug-resistant strains is mainly caused by inadequate treatment regimens, patient non-compliance, and the transmission of resistant strains (5). The spread of these resistant strains has made it increasingly difficult to control TB, especially in settings with high HIV prevalence, where immunocompromised individuals are at greater risk of developing active TB (6).

For effective treatment of TB, early and accurate detection of drug resistance is essential. Detection methods for drug resistance in Mtb have evolved, from traditional phenotypic methods such as the agar proportion method and liquid culture, to rapid molecular techniques like GeneXpert MTB/RIF and line probe assays (LPA). Molecular methods, which detect resistance mutations directly, provide faster results and can be particularly useful in

resource-limited settings where timely diagnosis is crucial for controlling the disease (7). However, phenotypic methods still remain the gold standard for confirming resistance to second-line drugs and provide more detailed information about the resistance profile (8).

The aim of this study is to evaluate the available diagnostic methods for the detection of drug resistance in Mtb, comparing the effectiveness of phenotypic and molecular techniques, and to assess their role in managing drug-resistant TB.

Aim and Objectives

Aim:

To assess the effectiveness and utility of various diagnostic methods for the detection of drug resistance in Mycobacterium tuberculosis, focusing on their impact on treatment outcomes and disease control.

Objectives:

1. To compare the performance of molecular and phenotypic methods in detecting drug-resistant M. tuberculosis strains.
2. To evaluate the clinical significance of early detection of drug resistance in TB treatment regimens.

Materials and Methods

This study was conducted at a tertiary care hospital between 2012 and 2013, focusing on sputum samples collected from patients diagnosed with pulmonary tuberculosis. A total of 120 sputum samples were included in the study. The inclusion criteria were patients aged 18–65 years with a confirmed diagnosis of pulmonary TB based on clinical and radiological findings. Exclusion criteria included patients with HIV co-infection, those who had received previous TB treatment, and those with extra-pulmonary TB.

Drug susceptibility testing (DST) was performed using the traditional agar proportion method (APM) for first-line drugs (isoniazid and rifampicin) and second-line drugs (fluoroquinolones, aminoglycosides). Molecular testing was performed using the GeneXpert MTB/RIF system to detect rifampicin resistance and line probe assays (LPA) for testing resistance to isoniazid, rifampicin, and second-line drugs. All diagnostic methods were validated by phenotypic culture-based techniques.

Results

Table 1: Prevalence of Drug Resistance in M. tuberculosis Isolates

Drug Resistance Category	Number of Isolates (n)	Percentage (%)
MDR-TB	35	29.17%
XDR-TB	10	8.33%
Rifampicin-resistant	20	16.67%
Isoniazid-resistant	25	20.83%

Table 2: Resistance Patterns of M. tuberculosis Isolates to Anti-TB Drugs

Drug	Resistant Isolates (n)	Percentage Resistant (%)
Isoniazid	55	45.83%
Rifampicin	50	41.67%
Fluoroquinolones	15	12.5%
Aminoglycosides	5	4.17%

Discussion

Drug resistance in Mycobacterium tuberculosis is an increasing concern, and the rapid and accurate detection of resistant strains is essential for appropriate treatment. The findings of this study showed that MDR-TB and XDR-TB were prevalent among the study population, with a significant proportion of Mtb isolates showing

resistance to first-line drugs, particularly isoniazid and rifampicin. The use of GeneXpert MTB/RIF and line probe assays for rapid molecular detection of rifampicin and isoniazid resistance was highly effective, providing results in a shorter time frame compared to traditional culture-based methods.

The high sensitivity and specificity of the GeneXpert MTB/RIF for detecting rifampicin resistance make it an invaluable tool in the early detection of MDR-TB, especially in settings with high TB burden and limited resources (9). Similarly, line probe assays (LPA) offered comprehensive resistance profiles, including second-line drug resistance, which is crucial for managing XDR-TB (10). These molecular methods provide critical information for treatment planning and help to avoid the spread of resistant strains.

While molecular methods are faster, they may not always provide comprehensive resistance profiles for all second-line drugs, which can be detected through phenotypic methods (11). The agar proportion method remains the gold standard for confirming resistance, especially to second-line drugs, but it is time-consuming and requires specialized laboratory facilities. Therefore, a combined approach, using molecular diagnostics for initial screening and phenotypic methods for confirmation, is recommended for managing drug-resistant TB.

The study's limitations include its relatively small sample size and exclusion of HIV-positive individuals, who are more likely to develop drug-resistant TB due to immunosuppression (4, 11). Further studies with larger sample sizes and inclusion of co-morbidities will help better understand the full spectrum of drug resistance in TB.

Conclusion

The detection of drug resistance in Mycobacterium tuberculosis is essential for effective TB treatment. Molecular diagnostic methods, such as GeneXpert MTB/RIF and line probe assays, offer rapid and accurate results, providing crucial information for the management of MDR-TB and XDR-TB. However, traditional phenotypic methods are still necessary for confirming resistance to second-line drugs. The integration of both molecular and phenotypic diagnostic methods into TB control programs is recommended for effective treatment and prevention of further resistance development.

References

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2012.
2. Migliori GB, Lange C, D'Ambrosio L, et al. Drug-resistant tuberculosis: the need for a global response. Eur Respir J. 2011;38(5):1173-81.
3. Espinal MA, Jaramillo E, Boulahbal F, et al. Multidrug-resistant tuberculosis: the experience in five continents. Clin Infect Dis. 2007;45(5):150-5.
4. Zignol M, van Gemert W, Falzon D, et al. The global incidence of extensively drug-resistant tuberculosis. Eur Respir J. 2012;39(4):155-8.
5. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors, and the management of resistance. Clin Chest Med. 2010;31(1):179-89.
6. Rao M, Chavan D, Shashidhar S, et al. Drug-resistant tuberculosis and its impact on treatment outcomes. Indian J Chest Dis Allied Sci. 2010;52(4):243-7.
7. Dorman SE, Nahid P. Diagnosis of multidrug-resistant tuberculosis. JAMA. 2010;303(9):927-8.
8. Mamahit Z, Sittichai J, Sanguanrungsirikul S, et al. Comparative evaluation of molecular and phenotypic drug resistance testing in Mycobacterium tuberculosis. BMC Infect Dis. 2010;10:115.
9. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance by use of an integrated PCR-based test. Lancet. 2010;375(9728):1730-5.
10. Bauer M, Yang Z, Keller K, et al. Evaluation of line probe assays for the detection of

multidrug-resistant tuberculosis. J Clin Microbiol. 2011;49(2):516-21.

11. Wells CD, Cegielski JP, Nelson LJ, et al. Extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380-7.